BRAF and Miyoshi myopathy: In recent years, treatment options for MM have expanded significantly, with immune checkpoint inhibitors (ICIs) (e.g., nivolumab, ipilimumab) and targeted therapies (such as BRAF inhibitors, MEK inhibitors, and C-KIT inhibitors) now being utilized as adjuvant treatments [9,10].